Cerebrolysin improved nerve fiber parameters in a diabetic neuropathy mouse model
Use a new needle every time Never reuse needles, as this can cause infections and blunt the sharpness, making injections more painful
Aunque existen numerosos estudios preclnicos y experiencias reportadas en protocolos experimentales, an se requiere mayor evidencia clnica para confirmar plenamente su perfil teraputico.
Key Safety Differentiators No IGF-1 elevation: AOD-9604 does not stimulate IGF-1, meaning it avoids risks such as organ/tissue overgrowth or acromegaly No glucose disruption: Clinical data shows it does not impair insulin sensitivity or worsen blood sugar regulation Comparable to placebo: In obesity trials, the incidence of adverse effects was similar to placebo groups, underscoring its tolerability Legal Status of AOD-9604 United States: AOD-9604 is not FDA-approved as a drug, dietary supplement, or weight loss therapy
These studies positioned Epitalon as a promising therapeutic in the emerging field of biogerontology the science of aging at the molecular and cellular levels
Datos humanos: comparado con la cantidad de investigacin en laboratorio/animales, la evidencia directa en humanos para Epitalon es limitada